Eli Lilly (LLY) Valuation After a Strong Multi-Year Run

Eli Lilly (LLY) is back in focus for many investors after a long stretch of strong multi-year total returns and significant scale, with a market value around US$761.7B and annual revenue of US$65.2B. The latest 9.8% 1-day share price return takes Eli Lilly to US$934.60, while the 1-year total shareholder return of 18.56% and 5-year total shareholder return above 4x suggest long-term momentum has remained.

Valuation After the Run

After such strong performance, investors are questioning whether Eli Lilly's valuation remains attractive. With a relatively high P/E ratio compared to the sector, investors need to assess whether future growth justifies the current valuation.

Key Growth Drivers

Eli Lilly's prospects hinge on the success of its blockbuster drugs, especially in diabetes and obesity treatments like Mounjaro and Zepbound. Its late-stage pipeline also provides additional growth opportunities.

Potential Risks

Risks include patent expirations, increasing competition in the obesity drug market, and regulatory pricing pressures. The high valuation also makes it vulnerable to corrections if growth expectations are not met.

What This Means for Investors

Eli Lilly remains a strong long-term investment, but the current valuation warrants caution. Investors should monitor clinical trial results and regulatory developments, focusing on the company's fundamentals rather than short-term price movements.